Developing a Conversation Aid to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice

Shared Decision Making for Atrial Fibrillation (SDM4AFib) Trial Investigators

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

Patient-centered care requires that treatments respond to the problematic situation of each patient in a manner that makes intellectual, emotional, and practical sense, an achievement that requires shared decision making (SDM). To implement SDM in practice, tools—sometimes called conversation aids or decision aids—are prepared by collating, curating, and presenting high-quality, comprehensive, and up-to-date evidence. Yet, the literature offers limited guidance for how to make evidence support SDM. Herein, we describe our approach and the challenges encountered during the development of Anticoagulation Choice, a conversation aid to help patients with atrial fibrillation and their clinicians jointly consider the risk of thromboembolic stroke and decide whether and how to respond to this risk with anticoagulation.

Original languageEnglish (US)
Pages (from-to)686-696
Number of pages11
JournalMayo Clinic Proceedings
Volume94
Issue number4
DOIs
StatePublished - Apr 2019

Bibliographical note

Funding Information:
Grant Support: This research was supported by award number R01HL131535 from the National Heart, Lung, and Blood Institute of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Grant Support: This research was supported by award number R01HL131535 from the National Heart, Lung, and Blood Institute of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Potential Competing Interests: Dr Gionfriddo has served as an expert consultant to Pfizer; has received grant support from Merck, AstraZeneca, Regeneron, and Takeda; and has been a lecturer or speaker for Hillcrest Medical Center and the Pharmaceutical Research and Manufacturers of America Foundation. The other authors report no competing interests. We thank all the clinicians and patients who generously contributed their time and opened the sanctity of their encounters to our research team. They are the reason we make sure that all the tools we develop and prove valuable remain in the public domain. Grant Support: This research was supported by award number R01HL131535 from the National Heart, Lung, and Blood Institute of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Potential Competing Interests: Dr Gionfriddo has served as an expert consultant to Pfizer; has received grant support from Merck, AstraZeneca, Regeneron, and Takeda; and has been a lecturer or speaker for Hillcrest Medical Center and the Pharmaceutical Research and Manufacturers of America Foundation. The other authors report no competing interests.

Publisher Copyright:
© 2018 Mayo Foundation for Medical Education and Research

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Review

Fingerprint

Dive into the research topics of 'Developing a Conversation Aid to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice'. Together they form a unique fingerprint.

Cite this